News >

Rini Discusses Future of Tivozanib, TKI/Immunotherapy Combos in mRCC

Brandon Scalea
Published: Monday, Mar 18, 2019

Brian I. Rini, MD

Brian I. Rini, MD

Although the VEGF TKI tivozanib (Fotivda) demonstrated superior progression-free survival (PFS) and tolerability compared with sunitinib (Sutent) in the TIVO-3 study, its role remains unclear following the FDA’s recommendation to not submit a new drug application (NDA) of tivozanib for patients with highly refractory, advanced or metastatic renal cell carcinoma (RCC).

In January 2019, the FDA stated that Aveo Oncology, the developer of tivozanib, should not submit the NDA following the preliminary overall survival (OS) findings from the phase III TIVO-3 trial in this patient population, adding that the data do not alleviate their concerns regarding a potential detriment in OS, which were outlined in a complete response letter issued in June 2013.1

Aveo Oncology previously stated that it plans to make an NDA filing decision following the availability of additional mature OS results.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x